Nischala Nannapaneni, MD
Clinical Cardiac Electrophysiology · Salt Lake City, UTNPI 1992967335
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (32.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Boston Scientific at 31.5% of the total.
Across 781 payments — averaging $72.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$18K
- Biosense Webster, Inc.$11K
- Abbott$7K
- Cook Incorporated$7K
- Medtronic$6K
- Medical Device Business Services, Inc.$3K
- plus $5K from 30 others
What the payments were for
- Consulting fees$13,42524%
- Speaking & faculty fees$8,73515%
- Travel & lodging$15,91628%
- Food & beverage$18,71733%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 217 | $17,936 |
| Biosense Webster, Inc. | 171 | $10,574 |
| Abbott | 97 | $7,028 |
| Cook Incorporated | 2 | $6,860 |
| Medtronic(2 entities) | 73 | $6,486 |
| Medical Device Business Services, Inc. | 12 | $3,152 |
| Stereotaxis Inc | 6 | $559 |
| Pfizer | 38 | $514 |
| E.r. Squibb & Sons, L.L.C. | 35 | $506 |
| Johnson & Johnson | 25 | $456 |
| Novartis | 21 | $409 |
| Atricure, Inc. | 6 | $336 |
| Cook Medical LLC | 4 | $310 |
| Amgen | 14 | $281 |
| Edwards Lifesciences | 2 | $194 |
| Acutus Medical, Inc. | 1 | $180 |
| Boehringer Ingelheim | 7 | $124 |
| Cardiva Medical, Inc. | 6 | $121 |
| Chiesi USA, Inc. | 5 | $104 |
| Merck | 6 | $94 |
| Merit Medical Systems Inc | 1 | $83 |
| Impulse Dynamics (USA) Inc. | 2 | $74 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| AstraZeneca | 6 | $70 |
| Philips North America LLC | 3 | $57 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Amarin Pharma, Inc. | 3 | $41 |
| Biotronik Inc. | 2 | $41 |
| Gilead | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evolution$7,025
- Watchman$6,595
- Carto 3$5,110
- Carto 3 System$2,715
- Farapulse$2,605
- AVEIR$1,447
- ALLURE$1,400
- EVERA MRI XT DR SURESCAN$1,242
- Allure Quadra RF CRT Pacemaker$1,200
- WATCHMAN Access System$829
- Accent Pacemaker$700
- Arctic Front$542
- Niobe$471
- Micra$284
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$179
- OCTARAY MAPPING CATHETER$170
- QDOT MICRO$143
- QDOT MICRO Catheter$124
- Quadra Assura CRT Defibrillator$121
How this compares
$56,915 in reported general payments places this provider in the 75th percentile of 29 clinical cardiac electrophysiology providers in Utah.
See all clinical cardiac electrophysiology providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 310 | $303,945 |
| XareltoRivaroxaban | 63 | $62,419 |
| MultaqDronedarone Hcl | 42 | $43,519 |
| Flecainide Acetate | 103 | $2,731 |
| Metoprolol Succinate | 236 | $2,383 |
| Amiodarone Hcl | 183 | $1,974 |
| Mexiletine Hcl | 30 | $1,778 |
| SotalolSotalol Hcl | 37 | $955 |
| Dofetilide | 12 | $886 |
| Digoxin | 33 | $883 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 39 | $877 |
| Carvedilol | 60 | $640 |
| Potassium Chloride | 31 | $478 |
| Losartan Potassium | 54 | $464 |
| Lisinopril | 31 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $514 | $303,945310 claims |
| Johnson & JohnsonXarelto | $456 | $62,41963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 clinical cardiac electrophysiology providers in Utah.
Other clinical cardiac electrophysiology in Salt Lake City
- Ravi RanjanSalt Lake City$345K
- John DaySalt Lake City$313K
- Roger FreedmanSalt Lake City$177K
- Helge LehmannSalt Lake City$49K
- Richard SheltonSalt Lake City$47K
- Anish ShahSalt Lake City$43K
- Qussay MarashlySalt Lake City$34K
- Michael CrawfordSalt Lake City$30K
- Jared MillerSalt Lake City$8K
- Travis WallSalt Lake City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.